Daiichi Sankyo’s Enhertu, Novartis’ Beovu, Novo’s Ozempic OK’ed for Listing on May 20

Japan’s all-important reimbursement policy panel on May 13 approved the listing of 18 drugs on May 20 including Daiichi Sankyo’s cancer drug Enhertu (trastuzumab deruxtecan) and Novartis’ wet age-related macular degeneration (AMD) treatment Beovu (brolucizumab). The Central Social Insurance Medical...read more